Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection Alone, and in Combination With Darolutamide (BAY 1841788), in Patients With Metastatic Castration Resistant Prostate Cancer
Conditions
Interventions
BAY2315497 Injection
Darolutamide(BAY1841788)
Locations
5
United States
Tulane Medical Center
New Orleans, Louisiana, United States
GU Research Network, LLC
Omaha, Nebraska, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
HUS, Meilahden sairaala
Helsinki, Finland
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, United Kingdom
Start Date
December 18, 2018
Primary Completion Date
August 25, 2022
Completion Date
October 31, 2024
Last Updated
November 8, 2024
NCT07285694
NCT04516161
NCT04052204
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions